Bolt 10-Q Flags Going Concern Despite $120M Prana-Era Raise
BOLT sits 91% above its 52-week low of $3.1.
Summary
Bolt's Q3 10-Q shows $15.0 million of cash at September 30 and a going-concern warning even after the $120.0 million October private placement, because the Series D Preferred can be cash-settled if conversion shares are not delivered. The filing also details up to 30,356,240 common shares issuable on conversion and revises prior-period financials.
Key Events · Earnings and Guidance · BOLT
-
Going-Concern Warning Persists
Management concluded substantial doubt exists about Bolt's ability to continue as a going concern for at least twelve months, citing the potential obligation to cash-settle Series D Preferred if conversion shares are not delivered.
-
Cash Falls to $15.0 Million
Cash, cash equivalents and marketable securities were $15.0 million at September 30, 2026, down from $18.1 million at Q2 2026, with a $19.5 million net loss for the nine months.
-
Series D Dilution Stack Detailed
Up to 30,356,240 common shares are issuable on Series D conversion if stockholders approve; accompanying warrants cover 50% of Series D shares at $8.5743 per common share and would raise about $60.0 million if fully exercised for cash.
-
Prior-Period Financials Revised
Bolt corrected immaterial errors in Q1/Q2 2026 and FY2025, including an EPS weighted-average share error, a $0.4 million R&D timing error and a $0.2 million equipment-sale error; no impact on total operating, investing or financing cash flows.
Analysis · BOLT · Life Sciences
Bolt closed Q3 with just $15.0 million in cash and investments, and even after the $120.0 million October private placement, management concluded substantial doubt exists about its ability to continue as a going concern within a year. The reason is structural: the Series D Preferred carries a cash-settlement right if Bolt fails to deliver common shares on conversion, so the raise does not cleanly count as equity runway until stockholders approve conversion. The filing also revises prior-period financials for immaterial errors and lays out the full dilution stack — up to 30,356,240 common shares on Series D conversion plus warrants for 50% of those shares at $8.5743, worth roughly $60.0 million if exercised for cash. The next hard gate is the stockholder vote on the Preferred Stock Conversion Proposal; failure there keeps the cash-settlement risk alive.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $5.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $3.10 to $7.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.